Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19

摘要

After publication of the original manuscript, we found thatincorrect citations were used in two places in themanuscript in the section Development of Remdesivir. Thecorrect citations with the full references below are as follows:“The study by Warren et al. found that GS-5734 reducedEBOV replication in HeLa cells with an IC50 ≈ 100 nM, and itretained potency in in vivo nonhuman primate EBOV infectionmodels, while GS-441524 was inactive.75,47 In addition todemonstrating activity against EBOV, Agostini et al. showedthat remdesivir also had antiviral activity against several otherviruses, including the coronavirus MERS, with an IC50 of 340nM in vitro.46”.